Drug Candidate Scores Interim Win in Rare Kidney Disease Trial Drug Candidate Scores Interim Win in Rare Kidney Disease Trial

Novartis said its experimental drug atrasentan was shown to have a positive effect on an indicator of kidney health in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Nephrology News Source Type: news